Pharmaceutical rivals Ranbaxy and Teva have reportedly decided to settle litigation that accused the companies of colluding on the sale of generic drugs, according to New York Attorney General Eric Schneiderman.
In a statement, Schneiderman announced that Japan’s Daiichi Sankyo, which owns Ranbaxy, and Israel-based Teva conspired to agree not to challenge each other’s generic drug sales for a period of six months after the brand name patent expires. Reports say that agreement affected the sale of the generic form of the world’s top-selling drug Lipitor.
The Attorney General said that “agreements between drug manufacturers to protect each other’s market positions violate principles of antitrust law, and can lead to higher drug prices.”
The companies reportedly made a “no challenge” agreement with each other in 2010 to not challenge each other’s filings for the exclusive right of the generic forms of pharmaceuticals.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Justice Department Moves to End NCAA Transfer Rule
May 30, 2024 by
CPI
Kenya’s Competition Authority Proposes Tougher Regulations on Big Tech
May 30, 2024 by
CPI
KKR Secures EU Antitrust Approval for $24 Billion Acquisition of Telecom Italia’s Fixed-Line Network
May 30, 2024 by
CPI
European Court Sides with Tech Giants in Italian Regulatory Dispute
May 30, 2024 by
CPI
US Steel and Nippon Steel Secure International Approvals for $14.9B Merger
May 30, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI